In breast cancer, it has been reported that breast cancer stem cells can induce metabolic reprogramming of tumour cells by secreting MIF to generate an immunosuppressive microenvironment, suggesting that therapeutic strategies targeting MIF could improve the efficacy of breast cancer immunotherapy [83]. The gene discussed is MIF; the disease is neoplasm.